Computational design of newly engineered DARPins as HER2 receptor inhibitors for breast cancer treatment

Maryam Beheshti Isfahani, Karim Mahnam , Hooria Seyedhosseini-Ghaheh , Hamid Mir Mohammad Sadeghi, Hossein Khanahmad, Vajihe Akbari, Jaleh Varshosaz

Abstract


Background and purpose: Human epidermal growth factor receptor 2 (HER2) is overexpressed in approximately 25% of breast cancer patients; therefore, its inhibition is a therapeutic target in cancer treatment.

Experimental approach: In this study, two new variants of designed ankyrin repeat proteins (DARPins), designated EG3-1 and EG3-2, were designed to increase their affinity for HER2 receptors. To this end, DARPin G3 was selected as a template, and six-point mutations comprising Q26E, I32V, T49A, L53H, K101R, and G124V were created on its structure. Furthermore, the 3D structures were formed through homology modeling and evaluated using molecular dynamic simulation. Then, both structures were docked to the HER2 receptor using the HADDOCK web tool, followed by 100 ns of molecular dynamics simulation for both DARPins / HER2 complexes.

Findings/Results: The theoretical result confirmed both structures’ stability. Molecular dynamics simulations reveal that the applied mutations on DARPin EG3-2 significantly improve the receptor binding affinity of DARPin.

Conclusion and implications: The computationally engineered DARPin EG3-2 in this study could provide a hit compound for the design of promising anticancer agents targeting HER2 receptors.


Keywords


Breast cancer; Designed ankyrin repeat proteins; Docking; Molecular dynamic simulation.

Full Text:

PDF

References


Kumar A, Singla A. Epidemiology of breast cancer: current figures and trends. In: Mehta S, Singla A, editors. Preventive oncology for the gynecologist. Singapore: Springer Singapore; 2019. pp. 335-339. DOI: 10.1007/978-981-13-3438-2_26.

Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687-697. DOI: 10.1016/S0140-6736(10)61121-X.

Ahmed N, Brawley VS, Hegde M, Robertson C, Ghazi A, Gerken C, et al. Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma. J Clin Oncol. 2015;33(15):1688-1696. DOI: 10.1200/JCO.2014.58.0225.

Reverdatto S, Burz DS, Shekhtman A. Peptide aptamers: development and applications. Curr Top Med Chem. 2015;15(12):1082-1101. DOI: 10.2174/1568026615666150413153143.

Goldstein R, Sosabowski J, Livanos M, Leyton J, Vigor K, Bhavsar G, et al. Development of the designed ankyrin repeat protein (DARPin) G3 for HER2 molecular imaging. Eur J Nucl Med Mol Imaging. 2015;42(2):288-301. DOI: 10.1007/s00259-014-2940-2.

Houlihan G, Gatti-Lafranconi P, Lowe D, Hollfelder F. Directed evolution of anti-HER2 DARPins by SNAP display reveals stability/function trade-offs in the selection process. Protein Eng Des Sel. 2015;28(9):269-279. DOI: 10.1093/protein/gzv029.

Plückthun A. Designed ankyrin repeat proteins (DARPins): binding proteins for research, diagnostics, and therapy. Annu Rev Pharmacol Toxicol. 2015;55:489-511. DOI: 10.1146/annurev-pharmtox-010611-134654.

Stüber JC, Richter CP, Bellón JS, Schwill M, König I, Schuler B, et al. Apoptosis-inducing anti-HER2 agents operate through oligomerization-induced receptor immobilization. Commun Biol. 2021;4(1):762,1-12. DOI: 10.1038/s42003-021-02253-4.

Hasenjäger A, Gillissen B, Müller A, Normand G, Hemmati PG, Schuler M, et al. Smac induces cytochrome c release and apoptosis independently from Bax/Bcl-xL in a strictly caspase-3-dependent manner in human carcinoma cells. Oncogene. 2004;23(26):4523-4535. DOI: 10.1038/sj.onc.1207594.

Godlewski MM, Gorka M, Lamparska-Przybysz M, Motyl T. Minute kinetics of proapoptotic proteins: BAX and Smac/DIABLO in living tumor cells revealed by homeostatic confocal microscopy. Cytotechnology. 2004;45(3):141-153. DOI: 10.1007/s10616-004-7255-x.

Fulda S. Promises and challenges of Smac mimetics as cancer therapeutics. Clin Cancer Res. 2015;21(22):5030-5036. DOI: 10.1158/1078-0432.CCR-15-0365.

Derakhshan A, Chen Z, Van Waes C. Therapeutic small molecules target inhibitor of apoptosis proteins in cancers with deregulation of extrinsic and intrinsic cell death pathways. Clin Cancer Res. 2017;23(6):1379-1387. DOI: 10.1158/1078-0432.CCR-16-2172.

Lv Z, Song X, Xu J, Jia Z, Yang B, Jia Y, et al. The modulation of Smac/DIABLO on mitochondrial apoptosis induced by LPS in Crassostrea gigas. Fish Shellfish Immunol. 2019;84:587-598. DOI: 10.1016/j.fsi.2018.10.035.

Kanwar JR, Shankaranarayanan JS, Gurudevan S, Kanwar RK. Aptamer-based therapeutics of the past, present and future: from the perspective of eye-related diseases. Drug Discov Today. 2014;19(9):1309-1321. DOI: 10.1016/j.drudis.2014.02.009.

Buglak AA, Samokhvalov AV, Zherdev AV, Dzantiev BB. Methods and applications of in silico aptamer design and modeling. Int J Mol Sci. 2020;21(22):8420,1-25. DOI: 10.3390/ijms21228420.

Seyedhosseini Ghaheh H, Ganjalikhany MR, Yaghmaei P, Pourfarzam M, Mir Mohammad Sadeghi H. Improving the solubility, activity, and stability of reteplase using in silico design of new variants. Res Pharm Sci. 2019;14(4):359-368. DOI: 10.4103/1735-5362.263560.

Payab N, Mahnam K, Shakhsi-Niaei M. Computational comparison of two new fusion proteins for multiple sclerosis. Res Pharm Sci. 2018;13(5):394-403. DOI: 10.4103/1735-5362.236832.

Riggio AI, Varley KE, Welm AL. The lingering mysteries of metastatic recurrence in breast cancer. Br J Cancer. 2021;124(1):13-26.DOI: 10.1038/s41416-020-01161-4.

GA. Jeffrey, W. Saenger. Hydrogen Bonding in Biological Structures. Berlin: Springer-Verlag; 2012. pp. 360-391

Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney DW, et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature. 2003;421(6924): 756-760. DOI: 10.1038/nature01392.

Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, et al. UCSF Chimera-a visualization system for exploratory research and analysis. J Comput Chem. 2004;25(13):1605-1612. DOI: 10.1002/jcc.20084.

Pimentel GC, McClellan AL. Hydrogen bonding. Annua Rev Phys Chem. 1971;22(1):347-385. DOI: 10.1146/annurev.pc.22.100171.002023.

Han J, Gao L, Wang J, Wang J. Application and development of aptamer in cancer: from clinical diagnosis to cancer therapy. J Cancer. 2020;11(23):6902-6915. DOI: 10.7150/jca.49532. eCollection 2020.

Vi C, Mandarano G, Shigdar S. Diagnostics and therapeutics in targeting HER2 breast cancer: a novel approach. Int J Mol Sci. 2021;22(11):6163,1-26. DOI: 10.3390/ijms22116163.

Wu X, Shaikh AB, Yu Y, Li Y, Ni S, Lu A, et al. Potential diagnostic and therapeutic applications of oligonucleotide aptamers in breast cancer. Int J Mol Sci. 2017;18(9):1851,1-23. DOI: 10.3390/ijms18091851.

Gijs M, Penner G, Blackler GB, Impens NR, Baatout S, Luxen A, et al. Improved aptamers for the diagnosis and potential treatment of HER2-positive cancer. Pharmaceuticals (Basel). 2016;9(2):29,1-21. DOI: 10.3390/ph9020029.

Osire T, Yang T, Xu M, Zhang X, Li X, Niyomukiza S, et al. Lys-Arg mutation improved the thermostability of Bacillus cereus neutral protease through increased residue interactions. World J Microbiol Biotechnol. 2019;35(11):173,1-11. DOI: 10.1007/s11274-019-2751-5.

Islam MM, Kobayashi K, Kidokoro SI, Kuroda Y. Hydrophobic surface residues can stabilize a protein through improved water-protein interactions. FEBS J. 2019;286(20):4122-4134. DOI: 10.1111/febs.14941. Epub 2019 Jun 17.

Seyedhosseini Ghaheh H, Sajjadi S, Shafiee F, Barzegari E, Moazen F, Mir Mohammad Sadeghi H. Rational design of a new variant of reteplase with optimized physicochemical profile and large-scale production in Escherichia coli. World J Microbiol Biotechnol. 2022;38(2):29. DOI: 10.1007/s11274-021-03204-1.

Pal S, Mitra RK. Investigation on the effect of nonpolar amino acids as macromolecular crowders on the stability of globular proteins. Chem Thermodyn Therm Anal. 2022;6:100044,1-6. DOI: 10.1016/ 2022.100044.

Dominguez C, Boelens R, Bonvin AM. HADDOCK: a protein-protein docking approach based on biochemical or biophysical information. J Am Chem Soc. 2003;125(7):1731-1737. DOI: 10.1021/ja026939x.

Mondal J, Friesner RA, Berne B. Role of desolvation in thermodynamics and kinetics of ligand binding to a kinase. J Chem Theory Comput. 2014;10(12):5696-5705. DOI: 10.1021/ct500584n.


Refbacks

  • There are currently no refbacks.


Creative Commons LicenseThis work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.